Nasdaq
$10.78▲ 0.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $563.5MShares out 52.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 4d agoAfter-hours26.10.21 05:564Ownership#●●●
4D Molecular Therapeutics, Inc.
Scott Bizily, an executive at 4D Molecular Therapeutics, reported a change in beneficial ownership of company securities effective October 16, 2026. This filing serves as a standard disclosure of insider equity movement to the SEC.…more
$10.78+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7After-hours26.10.08 06:114Ownership
4D Molecular Therapeutics, Inc.
Insider David Kirn of 4D Molecular Therapeutics, Inc. reported a change in beneficial ownership of company securities as of October 5, 2026. This filing serves as a standard Form 4 disclosure regarding the insider's equity holdings.…more
$10.78+0.05%vs prev closeView filingShare - 10.5After-hours26.10.06 07:23144Ownership
4D Molecular Therapeutics, Inc.
David Kirn, an insider at 4D Molecular Therapeutics, has filed Form 144 to propose the sale of company shares. This filing officially declares the executive's intent to sell a portion of their holdings in the open market.…more
$10.78+0.05%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16After-hours26.10.17 05:05#●●●
4DMT Announces New Employment Inducement Grants
4DMT granted stock options for 260,000 shares and 157,600 RSUs to 13 new non-executive employees. This is a standard equity-based compensation package for talent acquisition and does not have a material impact on the company's financial outlook.…more
$10.78+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.28Pre-market26.09.28 21:03
●●●●●●●● ●●●●● ●●●●●●
4D Molecular Therapeutics has initiated patient enrollment for the Phase 3 trial of its diabetic macular edema treatment, 4D-150. Previous two-year data demonstrated a 61% reduction in the number of required injections.…more
$10.78+0.05%vs prev closeShareBenzinga - 9.28Pre-market26.09.28 21:00
●●●●●●●● ●●●●● ●●●●●●
4DMT has commenced the global Phase 3 clinical trial for 4D-150, a treatment candidate for diabetic macular edema (DME). The company aims to reduce treatment burden by demonstrating sustained efficacy compared to standard anti-VEGF therapies.…more
$10.78+0.05%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report